1h Free Analyst Time
The publisher has been monitoring the male hypogonadism market and it is poised to grow by $684.95 mn during 2022-2026 progressing at a CAGR of 5.09% during the forecast period. The report on the male hypogonadism market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in the incidence of hypogonadism, increasing awareness about male hypogonadism and its treatment options, and growth in infertility rates.
The male hypogonadism market analysis includes the type segment and geographic landscape.
The male hypogonadism market is segmented as below:
By Type
- Klinefelters syndrome
- Kallmann syndrome
- Pituitary disorders
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the increasing inorganic growth strategies likely to fuel the market growth as one of the prime reasons driving the male hypogonadism market growth during the next few years. Also, robust R&D activities fueling the pipeline and treating low testosterone levels could reduce COVID-19 mortality will lead to sizable demand in the market.
The report on male hypogonadism market covers the following areas:
- Male hypogonadism market sizing
- Male hypogonadism market forecast
- Male hypogonadism market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading male hypogonadism market vendors that include AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. Also, the male hypogonadism market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Incremental Growth
Exhibit 07: Executive Summary - Data Table on Incremental Growth
Exhibit 08: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 09: Parent market
Exhibit 10: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021-2026
Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
4 Five Forces Analysis
4.1 Five forces summary
Exhibit 17: Five forces analysis - Comparison between2021 and 2026
4.2 Bargaining power of buyers
Exhibit 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
4.3 Bargaining power of suppliers
Exhibit 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
4.4 Threat of new entrants
Exhibit 20: Threat of new entrants - Impact of key factors in 2021 and 2026
4.5 Threat of substitutes
Exhibit 21: Threat of substitutes - Impact of key factors in 2021 and 2026
4.6 Threat of rivalry
Exhibit 22: Threat of rivalry - Impact of key factors in 2021 and 2026
4.7 Market condition
Exhibit 23: Chart on Market condition - Five forces 2021 and 2026
5 Market Segmentation by Type
5.1 Market segments
Exhibit 24: Chart on Type - Market share 2021-2026 (%)
Exhibit 25: Data Table on Type - Market share 2021-2026 (%)
5.2 Comparison by Type
Exhibit 26: Chart on Comparison by Type
Exhibit 27: Data Table on Comparison by Type
5.3 Klinefelters syndrome - Market size and forecast 2021-2026
Exhibit 28: Chart on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 29: Data Table on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 30: Chart on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
Exhibit 31: Data Table on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
5.4 Kallmann syndrome - Market size and forecast 2021-2026
Exhibit 32: Chart on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 33: Data Table on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
Exhibit 34: Chart on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
Exhibit 35: Data Table on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
5.5 Pituitary disorders - Market size and forecast 2021-2026
Exhibit 36: Chart on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Data Table on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
Exhibit 38: Chart on Pituitary disorders - Year-over-year growth 2021-2026 (%)
Exhibit 39: Data Table on Pituitary disorders - Year-over-year growth 2021-2026 (%)
5.6 Market opportunity by Type
Exhibit 40: Market opportunity by Type ($ million)
6 Customer Landscape
6.1 Customer landscape overview
Exhibit 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
7 Geographic Landscape
7.1 Geographic segmentation
Exhibit 42: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibit 43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 44: Chart on Geographic comparison
Exhibit 45: Data Table on Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibit 48: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibit 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
7.4 Europe - Market size and forecast 2021-2026
Exhibit 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibit 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
7.5 Asia - Market size and forecast 2021-2026
Exhibit 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibit 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
7.6 Rest of World (ROW) - Market size and forecast 2021-2026
Exhibit 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibit 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibit 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
7.7 US - Market size and forecast 2021-2026
Exhibit 62: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibit 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibit 64: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibit 65: Data Table on US - Year-over-year growth 2021-2026 (%)
7.8 Germany - Market size and forecast 2021-2026
Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
7.9 China - Market size and forecast 2021-2026
Exhibit 70: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibit 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibit 72: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibit 73: Data Table on China - Year-over-year growth 2021-2026 (%)
7.10 UK - Market size and forecast 2021-2026
Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
7.11 Canada - Market size and forecast 2021-2026
Exhibit 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibit 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibit 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
7.12 Market opportunity By Geographical Landscape
Exhibit 82: Market opportunity By Geographical Landscape ($ million)
8 Drivers, Challenges, and Trends
8.1 Market drivers
8.2 Market challenges
8.3 Impact of drivers and challenges
Exhibit 83: Impact of drivers and challenges in 2021 and 2026
8.4 Market trends
9 Vendor Landscape
9.1 Overview
9.2 Vendor landscape
Exhibit 84: Overview on Criticality of inputs and Factors of differentiation
9.3 Landscape disruption
Exhibit 85: Overview on factors of disruption
9.4 Industry risks
Exhibit 86: Impact of key risks on business
10 Vendor Analysis
10.1 Vendors covered
Exhibit 87: Vendors covered
10.2 Market positioning of vendors
Exhibit 88: Matrix on vendor position and classification
10.3 AbbVie Inc.
Exhibit 89: AbbVie Inc. - Overview
Exhibit 90: AbbVie Inc. - Product / Service
Exhibit 91: AbbVie Inc. - Key offerings
10.4 Bayer AG
Exhibit 92: Bayer AG - Overview
Exhibit 93: Bayer AG - Business segments
Exhibit 94: Bayer AG - Key offerings
Exhibit 95: Bayer AG - Segment focus
10.5 Eli Lilly and Co.
Exhibit 96: Eli Lilly and Co. - Overview
Exhibit 97: Eli Lilly and Co. - Product / Service
Exhibit 98: Eli Lilly and Co. - Key offerings
10.6 Endo International Plc
Exhibit 99: Endo International Plc - Overview
Exhibit 100: Endo International Plc - Business segments
Exhibit 101: Endo International Plc - Key news
Exhibit 102: Endo International Plc - Key offerings
Exhibit 103: Endo International Plc - Segment focus
10.7 Ferring B.V.
Exhibit 104: Ferring B.V. - Overview
Exhibit 105: Ferring B.V. - Product / Service
Exhibit 106: Ferring B.V. - Key offerings
10.8 IBSA Institute Biochimique SA
Exhibit 107: IBSA Institute Biochimique SA - Overview
Exhibit 108: IBSA Institute Biochimique SA - Product / Service
Exhibit 109: IBSA Institute Biochimique SA - Key offerings
10.9 Lipocine Inc.
Exhibit 110: Lipocine Inc. - Overview
Exhibit 111: Lipocine Inc. - Product / Service
Exhibit 112: Lipocine Inc. - Key offerings
10.10 Merck and Co. Inc.
Exhibit 113: Merck and Co. Inc. - Overview
Exhibit 114: Merck and Co. Inc. - Business segments
Exhibit 115: Merck and Co. Inc. - Key news
Exhibit 116: Merck and Co. Inc. - Key offerings
Exhibit 117: Merck and Co. Inc. - Segment focus
10.11 Pfizer Inc.
Exhibit 118: Pfizer Inc. - Overview
Exhibit 119: Pfizer Inc. - Product / Service
Exhibit 120: Pfizer Inc. - Key news
Exhibit 121: Pfizer Inc. - Key offerings
10.12 Teva Pharmaceutical Industries Ltd.
Exhibit 122: Teva Pharmaceutical Industries Ltd. - Overview
Exhibit 123: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibit 124: Teva Pharmaceutical Industries Ltd. - Key news
Exhibit 125: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibit 126: Teva Pharmaceutical Industries Ltd. - Segment focus
11 Appendix
11.1 Scope of the report
11.2 Inclusions and exclusions checklist
Exhibit 127: Inclusions checklist
Exhibit 128: Exclusions checklist
11.3 Currency conversion rates for US$
Exhibit 129: Currency conversion rates for US$
11.4 Research methodology
Exhibit 130: Research methodology
Exhibit 131: Validation techniques employed for market sizing
Exhibit 132: Information sources
11.5 List of abbreviations
Exhibit 133: List of abbreviations
List of ExhibitsExhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Incremental Growth
Exhibits 7: Executive Summary - Data Table on Incremental Growth
Exhibits 8: Executive Summary - Chart on Vendor Market Positioning
Exhibits 9: Parent market
Exhibits 10: Market Characteristics
Exhibits 11: Offerings of vendors included in the market definition
Exhibits 12: Market segments
Exhibits 13: Chart on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 14: Data Table on Global - Market size and forecast 2021-2026 ($ million)
Exhibits 15: Chart on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%)
Exhibits 17: Five forces analysis - Comparison between2021 and 2026
Exhibits 18: Chart on Bargaining power of buyers - Impact of key factors 2021 and 2026
Exhibits 19: Bargaining power of suppliers - Impact of key factors in 2021 and 2026
Exhibits 20: Threat of new entrants - Impact of key factors in 2021 and 2026
Exhibits 21: Threat of substitutes - Impact of key factors in 2021 and 2026
Exhibits 22: Threat of rivalry - Impact of key factors in 2021 and 2026
Exhibits 23: Chart on Market condition - Five forces 2021 and 2026
Exhibits 24: Chart on Type - Market share 2021-2026 (%)
Exhibits 25: Data Table on Type - Market share 2021-2026 (%)
Exhibits 26: Chart on Comparison by Type
Exhibits 27: Data Table on Comparison by Type
Exhibits 28: Chart on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
Exhibits 29: Data Table on Klinefelters syndrome - Market size and forecast 2021-2026 ($ million)
Exhibits 30: Chart on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
Exhibits 31: Data Table on Klinefelters syndrome - Year-over-year growth 2021-2026 (%)
Exhibits 32: Chart on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
Exhibits 33: Data Table on Kallmann syndrome - Market size and forecast 2021-2026 ($ million)
Exhibits 34: Chart on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
Exhibits 35: Data Table on Kallmann syndrome - Year-over-year growth 2021-2026 (%)
Exhibits 36: Chart on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
Exhibits 37: Data Table on Pituitary disorders - Market size and forecast 2021-2026 ($ million)
Exhibits 38: Chart on Pituitary disorders - Year-over-year growth 2021-2026 (%)
Exhibits 39: Data Table on Pituitary disorders - Year-over-year growth 2021-2026 (%)
Exhibits 40: Market opportunity by Type ($ million)
Exhibits 41: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 42: Chart on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 43: Data Table on Market share By Geographical Landscape 2021-2026 (%)
Exhibits 44: Chart on Geographic comparison
Exhibits 45: Data Table on Geographic comparison
Exhibits 46: Chart on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 47: Data Table on North America - Market size and forecast 2021-2026 ($ million)
Exhibits 48: Chart on North America - Year-over-year growth 2021-2026 (%)
Exhibits 49: Data Table on North America - Year-over-year growth 2021-2026 (%)
Exhibits 50: Chart on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 51: Data Table on Europe - Market size and forecast 2021-2026 ($ million)
Exhibits 52: Chart on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 53: Data Table on Europe - Year-over-year growth 2021-2026 (%)
Exhibits 54: Chart on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 55: Data Table on Asia - Market size and forecast 2021-2026 ($ million)
Exhibits 56: Chart on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 57: Data Table on Asia - Year-over-year growth 2021-2026 (%)
Exhibits 58: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 59: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million)
Exhibits 60: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 61: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%)
Exhibits 62: Chart on US - Market size and forecast 2021-2026 ($ million)
Exhibits 63: Data Table on US - Market size and forecast 2021-2026 ($ million)
Exhibits 64: Chart on US - Year-over-year growth 2021-2026 (%)
Exhibits 65: Data Table on US - Year-over-year growth 2021-2026 (%)
Exhibits 66: Chart on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million)
Exhibits 68: Chart on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 69: Data Table on Germany - Year-over-year growth 2021-2026 (%)
Exhibits 70: Chart on China - Market size and forecast 2021-2026 ($ million)
Exhibits 71: Data Table on China - Market size and forecast 2021-2026 ($ million)
Exhibits 72: Chart on China - Year-over-year growth 2021-2026 (%)
Exhibits 73: Data Table on China - Year-over-year growth 2021-2026 (%)
Exhibits 74: Chart on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 75: Data Table on UK - Market size and forecast 2021-2026 ($ million)
Exhibits 76: Chart on UK - Year-over-year growth 2021-2026 (%)
Exhibits 77: Data Table on UK - Year-over-year growth 2021-2026 (%)
Exhibits 78: Chart on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 79: Data Table on Canada - Market size and forecast 2021-2026 ($ million)
Exhibits 80: Chart on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 81: Data Table on Canada - Year-over-year growth 2021-2026 (%)
Exhibits 82: Market opportunity By Geographical Landscape ($ million)
Exhibits 83: Impact of drivers and challenges in 2021 and 2026
Exhibits 84: Overview on Criticality of inputs and Factors of differentiation
Exhibits 85: Overview on factors of disruption
Exhibits 86: Impact of key risks on business
Exhibits 87: Vendors covered
Exhibits 88: Matrix on vendor position and classification
Exhibits 89: AbbVie Inc. - Overview
Exhibits 90: AbbVie Inc. - Product / Service
Exhibits 91: AbbVie Inc. - Key offerings
Exhibits 92: Bayer AG - Overview
Exhibits 93: Bayer AG - Business segments
Exhibits 94: Bayer AG - Key offerings
Exhibits 95: Bayer AG - Segment focus
Exhibits 96: Eli Lilly and Co. - Overview
Exhibits 97: Eli Lilly and Co. - Product / Service
Exhibits 98: Eli Lilly and Co. - Key offerings
Exhibits 99: Endo International Plc - Overview
Exhibits 100: Endo International Plc - Business segments
Exhibits 101: Endo International Plc - Key news
Exhibits 102: Endo International Plc - Key offerings
Exhibits 103: Endo International Plc - Segment focus
Exhibits 104: Ferring B.V. - Overview
Exhibits 105: Ferring B.V. - Product / Service
Exhibits 106: Ferring B.V. - Key offerings
Exhibits 107: IBSA Institute Biochimique SA - Overview
Exhibits 108: IBSA Institute Biochimique SA - Product / Service
Exhibits 109: IBSA Institute Biochimique SA - Key offerings
Exhibits 110: Lipocine Inc. - Overview
Exhibits 111: Lipocine Inc. - Product / Service
Exhibits 112: Lipocine Inc. - Key offerings
Exhibits 113: Merck and Co. Inc. - Overview
Exhibits 114: Merck and Co. Inc. - Business segments
Exhibits 115: Merck and Co. Inc. - Key news
Exhibits 116: Merck and Co. Inc. - Key offerings
Exhibits 117: Merck and Co. Inc. - Segment focus
Exhibits 118: Pfizer Inc. - Overview
Exhibits 119: Pfizer Inc. - Product / Service
Exhibits 120: Pfizer Inc. - Key news
Exhibits 121: Pfizer Inc. - Key offerings
Exhibits 122: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits 123: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits 124: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits 125: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits 126: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits 127: Inclusions checklist
Exhibits 128: Exclusions checklist
Exhibits 129: Currency conversion rates for US$
Exhibits 130: Research methodology
Exhibits 131: Validation techniques employed for market sizing
Exhibits 132: Information sources
Exhibits 133: List of abbreviations
Executive Summary
The publisher recognizes the following companies as the key players in the global male hypogonadism market: AbbVie Inc., Aytu BioPharma Inc., Bayer AG, Bio Techne Corp., Diurnal Group Plc, Eli Lilly and Co., Endo International Plc, Ferring B.V., IBSA Institute Biochimique SA, Lipocine Inc., Merck and Co. Inc., Perrigo Co. Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd.Commenting on the report, an analyst from the research team said: `The latest trend gaining momentum in the market is increasing inorganic growth strategies likely to fuel the market growth.`
According to the report, one of the major drivers for this market is the increase in the incidence of hypogonadism.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Aytu BioPharma Inc.
- Bayer AG
- Bio Techne Corp.
- Diurnal Group Plc
- Eli Lilly and Co.
- Endo International Plc
- Ferring B.V.
- IBSA Institute Biochimique SA
- Lipocine Inc.
- Merck and Co. Inc.
- Perrigo Co. Plc
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
